ES2564290T3 - Inmunoensayo de flujo lateral para la activación de complemento y métodos de uso para evaluación del sitio de atención de trastornos asociados a complemento - Google Patents
Inmunoensayo de flujo lateral para la activación de complemento y métodos de uso para evaluación del sitio de atención de trastornos asociados a complemento Download PDFInfo
- Publication number
- ES2564290T3 ES2564290T3 ES11842681.6T ES11842681T ES2564290T3 ES 2564290 T3 ES2564290 T3 ES 2564290T3 ES 11842681 T ES11842681 T ES 11842681T ES 2564290 T3 ES2564290 T3 ES 2564290T3
- Authority
- ES
- Spain
- Prior art keywords
- complement
- ic3b
- lateral flow
- complement activation
- intact
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000024203 complement activation Effects 0.000 title abstract description 44
- 238000003018 immunoassay Methods 0.000 title abstract description 28
- 238000000034 method Methods 0.000 title description 31
- 230000000295 complement effect Effects 0.000 title description 27
- 238000011156 evaluation Methods 0.000 title 1
- 108010078015 Complement C3b Proteins 0.000 abstract description 52
- 238000003556 assay Methods 0.000 abstract description 17
- 239000012528 membrane Substances 0.000 abstract description 17
- 238000001514 detection method Methods 0.000 abstract description 15
- 210000001124 body fluid Anatomy 0.000 abstract description 14
- 239000010839 body fluid Substances 0.000 abstract description 14
- 239000012491 analyte Substances 0.000 abstract description 8
- 108010069112 Complement System Proteins Proteins 0.000 abstract description 4
- 102000000989 Complement System Proteins Human genes 0.000 abstract description 4
- 239000003550 marker Substances 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 description 36
- 102100022133 Complement C3 Human genes 0.000 description 34
- 101000901154 Homo sapiens Complement C3 Proteins 0.000 description 34
- 239000000523 sample Substances 0.000 description 33
- 208000014674 injury Diseases 0.000 description 27
- 230000002757 inflammatory effect Effects 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 230000009429 distress Effects 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- 241000283973 Oryctolagus cuniculus Species 0.000 description 14
- 230000004913 activation Effects 0.000 description 14
- 230000006378 damage Effects 0.000 description 13
- 230000008733 trauma Effects 0.000 description 13
- 241000283707 Capra Species 0.000 description 12
- 208000027418 Wounds and injury Diseases 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 12
- 241000287828 Gallus gallus Species 0.000 description 7
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000028709 inflammatory response Effects 0.000 description 6
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 5
- 206010040047 Sepsis Diseases 0.000 description 5
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 5
- 239000000090 biomarker Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 239000004074 complement inhibitor Substances 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 230000005291 magnetic effect Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000034486 Multi-organ failure Diseases 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- 108090000044 Complement Factor I Proteins 0.000 description 2
- 102100035431 Complement factor I Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 2
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 2
- 206010038687 Respiratory distress Diseases 0.000 description 2
- 208000009470 Ventilator-Associated Pneumonia Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000001138 tear Anatomy 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 101710131943 40S ribosomal protein S3a Proteins 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- 102000055157 Complement C1 Inhibitor Human genes 0.000 description 1
- 108700040183 Complement C1 Inhibitor Proteins 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- 229940124073 Complement inhibitor Drugs 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010049119 Emotional distress Diseases 0.000 description 1
- 102100030386 Granzyme A Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 208000028523 Hereditary Complement Deficiency disease Diseases 0.000 description 1
- 206010019860 Hereditary angioedema Diseases 0.000 description 1
- 101001009599 Homo sapiens Granzyme A Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 239000005041 Mylar™ Substances 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 108010052926 complement C3d,g Proteins 0.000 description 1
- 201000002388 complement deficiency Diseases 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000012125 lateral flow test Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920006267 polyester film Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/125—Adult respiratory distress syndrome
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40929710P | 2010-11-02 | 2010-11-02 | |
| US409297P | 2010-11-02 | ||
| PCT/US2011/058945 WO2012071145A1 (en) | 2010-11-02 | 2011-11-02 | Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2564290T3 true ES2564290T3 (es) | 2016-03-21 |
Family
ID=46146161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11842681.6T Active ES2564290T3 (es) | 2010-11-02 | 2011-11-02 | Inmunoensayo de flujo lateral para la activación de complemento y métodos de uso para evaluación del sitio de atención de trastornos asociados a complemento |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9182396B2 (https=) |
| EP (2) | EP2635702B1 (https=) |
| JP (1) | JP5859557B2 (https=) |
| AU (2) | AU2011332241B2 (https=) |
| CA (1) | CA2816423A1 (https=) |
| ES (1) | ES2564290T3 (https=) |
| MX (1) | MX340094B (https=) |
| WO (1) | WO2012071145A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8865164B2 (en) * | 2010-11-02 | 2014-10-21 | Kypha, Inc. | Detecting complement activation |
| WO2012071145A1 (en) * | 2010-11-02 | 2012-05-31 | Kypha, Inc. | Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders |
| US9110030B2 (en) | 2012-06-29 | 2015-08-18 | Daniel A. Kerschensteiner | Colorimetric gelatinase assay |
| US9863944B2 (en) | 2013-06-10 | 2018-01-09 | Asahi Kasei Fibers Corporation | Immunochromatographic diagnosis kit |
| WO2015168615A2 (en) * | 2014-05-02 | 2015-11-05 | Uab Research Foundation | Methods and compositions for diagnosis and treatment of meningitis |
| WO2017040243A1 (en) * | 2015-08-28 | 2017-03-09 | Kypha, Inc. | Methods for predicting flare and improving treatment of patients |
| KR102141591B1 (ko) * | 2016-05-13 | 2020-09-14 | 광주과학기술원 | 진단용 키트 |
| WO2019190877A1 (en) * | 2018-03-26 | 2019-10-03 | Alexion Pharmaceuticals, Inc. | High throughput method for measuring the protease activity of complement c3 convertase |
| EP3581934A1 (en) * | 2018-06-14 | 2019-12-18 | Otto-von-Guericke-Universität Magdeburg | Complement factors for diagnosis of low-grade infections in a human subject |
| WO2021222169A1 (en) * | 2020-04-27 | 2021-11-04 | Zinselmeyer Bernd H | Methods and systems for lateral flow immunoassay of various biological materials including sars-cov2 |
| EP4217744A4 (en) * | 2020-09-28 | 2024-11-06 | Allegheny Singer Research Institute | METHOD FOR DETERMINING A LEVEL OF A CELL FRAGMENT-BOUND COMPLEMENT ACTIVATION PRODUCT |
| US20240302366A1 (en) * | 2021-01-26 | 2024-09-12 | Sekisui Medical Co., Ltd. | Immunological assay method |
| AU2022271275A1 (en) * | 2021-05-07 | 2023-10-12 | Kypha, Inc. | Target measurement |
| WO2023192436A1 (en) * | 2022-03-31 | 2023-10-05 | Alexion Pharmaceuticals, Inc. | Singleplex or multiplexed assay for complement markers in fresh biological samples |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5212071A (en) * | 1988-04-01 | 1993-05-18 | The Johns Hopkins University | Nucleic acids encoding a human C3b/C4b receptor (CR1) |
| JPS595958B2 (ja) | 1975-12-30 | 1984-02-08 | トウキヨウケイソウ カブシキガイシヤ | 変量測定・伝送装置 |
| EP0097440B1 (en) * | 1982-06-14 | 1986-09-24 | The Upjohn Company | Method and kit for removing and assaying complement system fragments |
| SE452065B (sv) | 1986-04-11 | 1987-11-09 | Ulf R Nilsson | Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning |
| SE452067B (sv) * | 1986-04-11 | 1987-11-09 | Ulf R Nilsson | Reagens for och sett vid immunkemisk bestemning av c3a |
| IL89790A (en) * | 1988-04-01 | 2002-05-23 | Johns Hopking University | Nucleic acid sequences that encode and cells that produce cr1 protein and methods of production and purification |
| WO2003062824A1 (en) * | 2002-01-23 | 2003-07-31 | Boditech Inc. | Lateral flow quantitative assay method and strip and laser-induced fluoerescence detection device therefor |
| WO2004093636A2 (en) * | 2003-04-17 | 2004-11-04 | Rauno Joks | PLASMA C5a LEVELS AS AN INDICATOR OF ASTHMA SEVERITY |
| ZA200510325B (en) | 2003-06-13 | 2008-04-30 | Univ Pittsburgh | Monitoring immunologic, hematologic and inflammatory diseases |
| ES2321105T3 (es) | 2003-09-29 | 2009-06-02 | Peas Institut Ab | Determinacion rapida de formas diferentes del factor de crecimiento de hepatocitos (hgf) en los fluidos corporales. |
| US20050255533A1 (en) | 2004-02-10 | 2005-11-17 | Brendan Bioscience, Llc | Comprehensive food allergy test |
| US20060292700A1 (en) * | 2005-06-22 | 2006-12-28 | Naishu Wang | Diffused interrupted lateral flow immunoassay device and method |
| WO2006124888A2 (en) | 2005-05-16 | 2006-11-23 | Brendan Bioscience, Llc | Detection of antigen specific immunocomplexes |
| US7910381B2 (en) | 2005-10-13 | 2011-03-22 | BioAssay Works | Immuno gold lateral flow assay |
| US8192742B2 (en) * | 2007-03-23 | 2012-06-05 | NovelMed Therapeutics | Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof |
| EP2313527A4 (en) * | 2008-07-15 | 2012-11-21 | Rapid Pathogen Screening Inc | Lateral flow NUCLEIC DETECTOR |
| MX2011007030A (es) * | 2008-12-30 | 2011-07-20 | Centocor Ortho Biotech Inc | Marcadores sericos que predicen la respuesta clinica a los anticuerpos anti-factor de necrosis tumoral alfa en pacientes con espondilitis anquilosante. |
| US9291622B2 (en) * | 2009-05-21 | 2016-03-22 | Apellis Pharmaceuticals, Inc. | Complement assays and uses thereof |
| WO2012071145A1 (en) | 2010-11-02 | 2012-05-31 | Kypha, Inc. | Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders |
| US8865164B2 (en) | 2010-11-02 | 2014-10-21 | Kypha, Inc. | Detecting complement activation |
-
2011
- 2011-11-02 WO PCT/US2011/058945 patent/WO2012071145A1/en not_active Ceased
- 2011-11-02 US US13/287,432 patent/US9182396B2/en active Active
- 2011-11-02 ES ES11842681.6T patent/ES2564290T3/es active Active
- 2011-11-02 JP JP2013537784A patent/JP5859557B2/ja active Active
- 2011-11-02 AU AU2011332241A patent/AU2011332241B2/en active Active
- 2011-11-02 CA CA2816423A patent/CA2816423A1/en not_active Abandoned
- 2011-11-02 EP EP11842681.6A patent/EP2635702B1/en active Active
- 2011-11-02 MX MX2013004960A patent/MX340094B/es active IP Right Grant
- 2011-11-02 EP EP15199549.5A patent/EP3095876A1/en not_active Withdrawn
-
2015
- 2015-08-13 US US14/825,437 patent/US9939446B2/en active Active
-
2016
- 2016-02-05 AU AU2016200772A patent/AU2016200772B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2635702B1 (en) | 2016-02-03 |
| JP5859557B2 (ja) | 2016-02-10 |
| MX2013004960A (es) | 2013-12-16 |
| US9939446B2 (en) | 2018-04-10 |
| MX340094B (es) | 2016-06-27 |
| US20120141457A1 (en) | 2012-06-07 |
| AU2011332241A2 (en) | 2013-06-13 |
| AU2011332241B2 (en) | 2015-11-26 |
| EP2635702A4 (en) | 2014-04-02 |
| US20150346211A1 (en) | 2015-12-03 |
| WO2012071145A1 (en) | 2012-05-31 |
| AU2016200772A1 (en) | 2016-02-25 |
| AU2011332241A1 (en) | 2013-05-23 |
| CA2816423A1 (en) | 2012-05-31 |
| JP2014502347A (ja) | 2014-01-30 |
| AU2016200772B2 (en) | 2018-02-01 |
| US9182396B2 (en) | 2015-11-10 |
| EP2635702A1 (en) | 2013-09-11 |
| EP3095876A1 (en) | 2016-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2564290T3 (es) | Inmunoensayo de flujo lateral para la activación de complemento y métodos de uso para evaluación del sitio de atención de trastornos asociados a complemento | |
| Stocker et al. | Neonatal Procalcitonin Intervention Study (NeoPInS): Effect of Procalcitonin-guided decision making on duration of antibiotic therapy in suspected neonatal early-onset sepsis: A multi-centre randomized superiority and non-inferiority Intervention Study | |
| Medina Fernández et al. | Postoperative time course and utility of inflammatory markers in patients with ovarian peritoneal carcinomatosis treated with neoadjuvant chemotherapy, cytoreductive surgery, and HIPEC | |
| ES2684976T3 (es) | Biomarcadores maternos para diabetes gestacional | |
| ES2755623T3 (es) | Procedimiento de detección de coagulación intravascular diseminada o coagulación intravascular diseminada infecciosa | |
| Ranjan et al. | Midodrine plus propranolol versus propranolol alone in preventing first bleed in patients with cirrhosis and severe ascites: a randomized controlled trial | |
| ES2842283T3 (es) | Métodos y composiciones para el diagnóstico y tratamiento de la meningitis | |
| ES2711921T3 (es) | Detección de la activación del complemento | |
| ES2939143T3 (es) | Biomarcadores para una politerapia que comprende lenvatinib y everolimus | |
| US20130084587A1 (en) | Levels of cytokeratins in blood and body fluids as biomarkers for cancer screening, diagnosis and treatment monitoring | |
| Redkin et al. | Testing antithrombin level allows predicting a clinical outcome of sepsis | |
| CN111650372A (zh) | 载脂蛋白c1在作为胃癌诊断及预后评价生物标记物中的应用 | |
| US20190056412A1 (en) | Methods and compositions for determining fortilin levels | |
| JP6555711B2 (ja) | 非解離性大動脈瘤の疾患活動性の判定方法 | |
| KR102903735B1 (ko) | 담관암종의 표지자로서의 timp1 | |
| Kim et al. | Serum REG3α as a Biomarker for Clinical and Endoscopic Activity in Ulcerative Colitis | |
| RU2609839C1 (ru) | Способ дифференциальной диагностики гиперчувствительности к яду пчелы (apis mellifera) | |
| Zeynettin et al. | The value of procalsitonin in determining the severity acute pancreatitis cases | |
| El-Garem et al. | Use of the urinary trypsinogen-2 dipstick test in early diagnosis of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP) | |
| HK1234826B (en) | Methods and compositions for diagnosis and treatment of meningitis | |
| HK1234826A1 (en) | Methods and compositions for diagnosis and treatment of meningitis | |
| CN109953744A (zh) | 用于取得关于vegf-a的值的方法及装置 | |
| JP2020505389A (ja) | 子宮内膜症の予後及び治療におけるｃｄ７１受容体の使用 | |
| JP2007139731A (ja) | ジャーミノーマの判定法 | |
| WO2012152970A1 (es) | Método de diagnóstico del ictus isquémico |